Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,149.36 -10.24 (-0.88%)

Official Closing Price Updated: 7:00 PM EDT, Sep 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Revolution Medicines Got Its Breakthrough—What Moves It Next? ↗

September 04, 2026

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

Via MarketBeat

If a Bear Market Is Coming, Is VOO or VTI the Safer Investment? ↗

September 04, 2026

You can't go wrong with either, but one has a key difference that gives it the edge.

Via The Motley Fool

Topics ETFs

2 Stocks Down 8% or More That Are Screaming Buys Right Now ↗

September 04, 2026

You might regret ignoring these companies at current levels.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly (NYSE:LLY) Demonstrates High-Growth Leadership and Momentum ↗

August 26, 2026

Via Chartmill

Great News for Eli Lilly Stock Investors ↗

September 03, 2026

There is no end in sight for the company's incredible momentum.

Via The Motley Fool

Eli Lilly Just Announced a Major Acquisition. Here's What It Means. ↗

September 02, 2026

The drug giant added to its immunotherapy portfolio.

Via The Motley Fool

Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ ↗

September 02, 2026

Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns.

Via The Motley Fool

Topics ETFs

Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity ↗

September 02, 2026

Eli Lilly's $2.875 billion Merida Biosciences deal expands its immunology pipeline, as strong GLP-1 growth continues while LLY shares trail the broader health care sector.

Via MarketBeat

Peptides Costa Rica Announces New Transparency Standard Amid Growing National Scrutiny of the Peptide Market

September 01, 2026

Jacó, Puntarenas - September 01, 2026 - Peptides Costa Rica has introduced a new transparency standard designed to give researchers and buyers clearer access to product verification information, a...

Via Press Advantage

Topics Supply Chain

Vanguard Health Care ETF vs Simplify Health Care ETF ↗

September 01, 2026

Vanguard offers broad exposure at 0.09% cost with 1.5% yield, while Simplify's active strategy returned 32.4% over one year but charges 0.51%.

Via The Motley Fool

Topics ETFs

This New Zepbound Study Could Be Great News for Eli Lilly Investors ↗

September 01, 2026

The high-flying healthcare leader looks unstoppable right now.

Via The Motley Fool

Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors. ↗

August 31, 2026

Hardly for the first time recently, the company is making a pricey acquisition.

Via The Motley Fool

Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. ↗

August 30, 2026

The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.

Via The Motley Fool

Should Eli Lilly Investors Be Worried About a Threat From Amylyx? ↗

August 30, 2026

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Via The Motley Fool

3 Things That Matter Most for Eli Lilly Now ↗

August 29, 2026

Eli Lilly is the leader in the GLP-1 space, but the company can't rest on its laurels.

Via The Motley Fool

Topics Intellectual Property

Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly? ↗

August 29, 2026

Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.

Via The Motley Fool

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 29, 2026

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

Via The Motley Fool

2 Mega-Cap Stocks Worth Investigating and 1 Facing Headwinds

August 28, 2026

Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that mos...

Via StockStory

3 Stocks Under $50 That Concern Us

August 28, 2026

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...

Via StockStory

3 Big Reasons to Love Eli Lilly (LLY)

August 28, 2026

Eli Lilly trades at $1,175 per share and has stayed right on track with the overall market, gaining 15.4% over the last six months. At the same time, the S&P...

Via StockStory

Veeva Systems Q2 Earnings Call Highlights ↗

August 26, 2026

Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded...

Via MarketBeat

Topics Artificial Intelligence Earnings

Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs ↗

August 26, 2026

New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.

Via Benzinga

Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week ↗

August 26, 2026

Eli Lilly and Co. shares are trading lower Wednesday, pulling back from last week's record high despite positive real-world data on Zepbound.

Via Benzinga

VivoSim Labs (NASDAQ: VIVS): 10,000 Compounds to 1 Drug with AI-Powered 3D Human Toxicology

August 26, 2026

Via AB Newswire

Topics Artificial Intelligence

Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now

August 26, 2026

Via AB Newswire

Topics Artificial Intelligence

What's going on in today's session: S&P500 movers ↗

August 26, 2026

Via Chartmill

Is It Too Late to Buy Eli Lilly? Billionaire Ken Griffin Doesn't Think So. He Nearly Quadrupled His Stake in the Pharma Stock in Q2. ↗

August 26, 2026

Eli Lilly looks like a strong long-term investment thanks to its booming obesity drugs and Alzheimer's treatment, and to Billionaire Ken Griffin's investment.

Via The Motley Fool

Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus ↗

August 26, 2026

VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.

Via The Motley Fool

Topics ETFs

Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal ↗

August 26, 2026

Duquesne Family Office has beefed up its healthcare holdings.

Via The Motley Fool

2 Stocks That Could Capitalize on the GLP-1 Boom ↗

August 25, 2026

They aren't the most prominent names in the GLP-1 space, but they are worth a second look.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.